Compare Celestica Inc (CLS) vs Rocket Lab USA Inc (RKLB) Price & Performance

Celestica (CLS) trades at $345.18, down 4.08% over 24 hours, with technical indicators showing a bearish trend near key support at $339. The company demonstrates strong fundamentals with Q1 2026 EPS of $2.16 beating estimates, revenue growth accelerating to 55.55% YoY, and a robust ROE of 52.45%. Recent leadership appointments and raised FY2026 revenue guidance to $19 billion reflect operational momentum amid AI and data center demand tailwinds.

Wall Street maintains a bullish outlook with 63% buy ratings and a $440.10 consensus price target, implying 27% upside. Key risks include competitive pressures in the EMS sector and execution challenges in margin expansion. The stock's high P/E of 41.82 warrants monitoring, but earnings beats and institutional confidence support a positive investment case pending Q2 results on July 28, 2026.

Rocket Lab (RKLB) trades at $76.73, down 5.32% over 24 hours, testing key support near $75 amid a bearish technical trend. The company reported Q1 2026 EPS of -$0.02, beating expectations, while revenue reached $601.80M in 2025 with a net loss of -$198.21M. Analyst sentiment remains bullish with a $119.10 consensus price target, supported by recent strategic moves like the Iridium acquisition announced July 13, 2026.

The outlook hinges on execution of growth initiatives and path to profitability, with risks including high cash burn and competitive pressures. Upside potential exists if operational efficiencies improve and satellite revenue scales, but investors face volatility from negative margins and sector headwinds.